1. Home
  2. RBCAA vs NRIX Comparison

RBCAA vs NRIX Comparison

Compare RBCAA & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RBCAA
  • NRIX
  • Stock Information
  • Founded
  • RBCAA 1974
  • NRIX 2009
  • Country
  • RBCAA United States
  • NRIX United States
  • Employees
  • RBCAA N/A
  • NRIX N/A
  • Industry
  • RBCAA Major Banks
  • NRIX Biotechnology: Pharmaceutical Preparations
  • Sector
  • RBCAA Finance
  • NRIX Health Care
  • Exchange
  • RBCAA Nasdaq
  • NRIX Nasdaq
  • Market Cap
  • RBCAA 1.3B
  • NRIX 1.3B
  • IPO Year
  • RBCAA 1998
  • NRIX 2020
  • Fundamental
  • Price
  • RBCAA $76.21
  • NRIX $22.92
  • Analyst Decision
  • RBCAA
  • NRIX Strong Buy
  • Analyst Count
  • RBCAA 0
  • NRIX 15
  • Target Price
  • RBCAA N/A
  • NRIX $29.33
  • AVG Volume (30 Days)
  • RBCAA 19.6K
  • NRIX 953.2K
  • Earning Date
  • RBCAA 10-18-2024
  • NRIX 10-11-2024
  • Dividend Yield
  • RBCAA 2.14%
  • NRIX N/A
  • EPS Growth
  • RBCAA 15.67
  • NRIX N/A
  • EPS
  • RBCAA 5.18
  • NRIX N/A
  • Revenue
  • RBCAA $324,440,000.00
  • NRIX $56,424,000.00
  • Revenue This Year
  • RBCAA N/A
  • NRIX N/A
  • Revenue Next Year
  • RBCAA $4.24
  • NRIX $7.17
  • P/E Ratio
  • RBCAA $14.72
  • NRIX N/A
  • Revenue Growth
  • RBCAA 5.10
  • NRIX N/A
  • 52 Week Low
  • RBCAA $46.55
  • NRIX $5.65
  • 52 Week High
  • RBCAA $79.75
  • NRIX $29.56
  • Technical
  • Relative Strength Index (RSI)
  • RBCAA 63.27
  • NRIX 38.26
  • Support Level
  • RBCAA $75.32
  • NRIX $26.48
  • Resistance Level
  • RBCAA $79.53
  • NRIX $29.56
  • Average True Range (ATR)
  • RBCAA 2.42
  • NRIX 1.56
  • MACD
  • RBCAA 0.51
  • NRIX -0.19
  • Stochastic Oscillator
  • RBCAA 76.18
  • NRIX 0.52

About RBCAA Republic Bancorp Inc.

Republic Bancorp Inc operates as a financial institution that provides both traditional and non-traditional banking products through six reportable segments. It has traditional banking which generates the majority of revenue, warehouse, mortgage banking, Tax Refund Solutions (TRS), Republic Payment Solutions segment, and Republic Credit Solutions (RCS) business segments. The business activities of these segments include retail mortgage and commercial lending, construction and land development lending, internet lending, correspondent and indirect lending and also private banking, treasury management services, internet, and mobile banking, bank acquisitions, short-term revolving credit facilities, fixed-term residential real estate loans and receipt and payment of federal.

About NRIX Nurix Therapeutics Inc. Common stock

Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies. Its drug candidate from E3 ligase inhibitor portfolio, NX-1607, is an orally available CBL-B inhibitor for immuno-oncology indications.

Share on Social Networks: